allogeneic cellular melanoma vaccine (New York Medical College)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameallogeneic cellular melanoma vaccine (New York Medical College)
Drug Alias NameDC-MelVacDC-rIL-2-VMO
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNew York Medical College
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNew York Medical College
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A